KarimChamieMD
Urology • Los Angeles, CASurgical Oncology
Associate Professor, Urology, UCLA School of Medicine
Dr. Chamie is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
UCLA Medical Center
200 Medical Plaza, Suite 140
Los Angeles, CA 90095Phone+1 310-794-2858Fax+1 310-794-2858- Is this information wrong?
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Urologic Surgical Oncology, 2011 - 2012- Ronald Reagan UCLA Medical CenterFellowship, Health Services Research, 2010 - 2011
UCLA School of Public HealthMSHS, Health Services Research, 2009 - 2010
University of California Davis HealthResidency, Urology, 2005 - 2009- University of California Davis HealthResidency, Surgery, 2003 - 2005
Keck School of Medicine of the University of Southern CaliforniaClass of 2003
Certifications & Licensure
CA State Medical License 2004 - 2024- American Board of Urology Urology
Awards, Honors, & Recognition
- Research Career Development Award STOP CANCER Research Foundation
- SEED Grant Phase One Foundation
- SEED Grant HH Lee Surgical Society
Clinical Trials
- Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer Start of enrollment: 2010 Dec 01
- Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer Start of enrollment: 2014 Mar 01
- A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT Start of enrollment: 2013 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- Gain of Chromosome 5q Predicts a Favorable Prognosis in Localized Renal Cell Carcinoma.Cedric Lebacle, Aydin Pooli, Brian Shuch, Nagesh Rao, Karim Chamie, Nils Kroeger, Izak Faiena, Sandy Liu, Erika L Wood, Arie Belldegrun, Alexandra Drakaki, Allan J Pan...> ;Cancer Investigation. 2024 Jan 1
- Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin‒Unresponsive Nonmuscle-Invasive Bladder Cancer.Huang, M., Bhar, P., Spilman, P., Sender, L., Reddy, S., Chamie, K., Chang, S., Kramolowsky, E., Gonzalgo, M., Soon-Shiong, P.> ;Urology Practice. 2024 Mar 1
- Interruptions in bladder cancer care during the COVID-19 public health emergency.John L Gore, Kristin Follmer, Jason Reynolds, Michael Nash, Christopher B Anderson, James W F Catto, Karim Chamie, Siamak Daneshmand, Rian Dickstein, Tullika Garg, Sco...> ;Urologic Oncology. 2024 Apr 1
- Join now to see all
Journal Articles
- Radical Prostatectomy Then and Now: Surgical Overtreatment of Prostate Cancer Is Declining from 2009 to 2016 at a Tertiary Referral CenterAmirali Salmasi, Izak Faiena, Karim Chamie, Urologic Oncology
Press Mentions
How Bladder Cancer Immunostimulant N-803 May Shake Things UpApril 20th, 2023- AUA 2022: Late-Breaking Plenary HighlightsJuly 27th, 2022
- ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-Free in Phase 2/3 TrialSeptember 13th, 2021
- Join now to see all
Grant Support
- Health Disparities in Prostate CancerNIH Loan Repayment Program2012–2016
- Quality of Care in Patients with Bladder CancerAmerican Cancer Society2009–2011
- Quality Of Care In Patients With Bladder Cancer.National Cancer Institute2009–2011
Professional Memberships
- Member
- Member
- Member
- Society of Urologic OncologyMember
Other Languages
- Spanish
Hospital Affiliations
Ronald Reagan UCLA Medical CenterLos Angeles, California- UCLA Medical Center-Santa MonicaSanta Monica, California
Olive View-UCLA Medical CenterSylmar, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
